GLUE
$16.03
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Intraday
Recent News
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans
Monte Rosa Therapeutics (NASDAQ:GLUE) highlighted progress across its molecular glue degrader pipeline during a presentation at the Barclays 28th Annual Global Healthcare Conference, with Chief Medical Officer Filip Janku outlining upcoming clinical milestones in inflammation and immunology (I&I
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -17.02% and -72.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics: Q4 Earnings Snapshot
BOSTON (AP) — Monte Rosa Therapeutics Inc. GLUE) on Tuesday reported a loss of $46.1 million in its fourth quarter. The Boston-based company said it had a loss of 55 cents per share.
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?